Recurrence in lobular carcinoma of the breast: A 14-year review

IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of Medical Imaging and Radiation Oncology Pub Date : 2024-05-28 DOI:10.1111/1754-9485.13715
Nathan Burns, Anita Bourke
{"title":"Recurrence in lobular carcinoma of the breast: A 14-year review","authors":"Nathan Burns,&nbsp;Anita Bourke","doi":"10.1111/1754-9485.13715","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The two most common types of breast cancer are invasive or infiltrating ductal carcinoma (IDC) and invasive or infiltrating lobular carcinoma (ILC) (Pestalozzi <i>et al</i>., <i>J. Clin. Oncol.</i>, 26, 2008, 3006). Between 5% and 15% of invasive breast carcinomas are lobular carcinomas (Pestalozzi <i>et al</i>., <i>J. Clin. Oncol.</i>, 26, 2008, 3006; Dossus and Benusiglio, <i>Breast Cancer Res</i>., 17, 2015, 37; Braunstein <i>et al</i>., <i>Breast Cancer Res. Treat</i>., 149, 2015, 555). The paucity of data relating to recurrence rates of lobular cancers prompted this study.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective cohort study of all cases of lobular breast carcinoma reported to the Western Australia Cancer Registry with the clinical and pathological details between 2000 and 2014.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall, 2463 subjects with a total of 2526 events of invasive lobular carcinoma of the breast. 11/2463 (0.45%) subjects met criteria for local recurrence of invasive lobular breast cancer, with an incidence of 1 in 224.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>There are clinical implications for the management and follow-up for patients with a diagnosis of lobular cancer of the breast. Due to the low recurrence rate, now, the standard practice in our institution does not offer magnetic resonance imaging (MRI) as part of the follow-up for ILC patients. Other centres should establish local recurrence rates to aid development of appropriate management protocols.</p>\n </section>\n </div>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":"68 5","pages":"523-529"},"PeriodicalIF":2.2000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Imaging and Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1754-9485.13715","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The two most common types of breast cancer are invasive or infiltrating ductal carcinoma (IDC) and invasive or infiltrating lobular carcinoma (ILC) (Pestalozzi et al., J. Clin. Oncol., 26, 2008, 3006). Between 5% and 15% of invasive breast carcinomas are lobular carcinomas (Pestalozzi et al., J. Clin. Oncol., 26, 2008, 3006; Dossus and Benusiglio, Breast Cancer Res., 17, 2015, 37; Braunstein et al., Breast Cancer Res. Treat., 149, 2015, 555). The paucity of data relating to recurrence rates of lobular cancers prompted this study.

Methods

A retrospective cohort study of all cases of lobular breast carcinoma reported to the Western Australia Cancer Registry with the clinical and pathological details between 2000 and 2014.

Results

Overall, 2463 subjects with a total of 2526 events of invasive lobular carcinoma of the breast. 11/2463 (0.45%) subjects met criteria for local recurrence of invasive lobular breast cancer, with an incidence of 1 in 224.

Conclusion

There are clinical implications for the management and follow-up for patients with a diagnosis of lobular cancer of the breast. Due to the low recurrence rate, now, the standard practice in our institution does not offer magnetic resonance imaging (MRI) as part of the follow-up for ILC patients. Other centres should establish local recurrence rates to aid development of appropriate management protocols.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺小叶癌复发:14 年回顾。
导言:两种最常见的乳腺癌类型是浸润性或浸润性导管癌(IDC)和浸润性或浸润性小叶癌(ILC)(Pestalozzi 等人,J. Clin. Oncol.,26,2008,3006)。5%到 15%的浸润性乳腺癌是小叶癌(Pestalozzi 等人,J. Clin.Oncol.,26,2008,3006;Dossus 和 Benusiglio,Breast Cancer Res.,17,2015,37;Braunstein 等人,Breast Cancer Res. Treat.,149,2015,555)。有关小叶癌复发率的数据很少,这促使了本研究的开展:方法:对2000年至2014年间向西澳大利亚癌症登记处报告的所有乳腺小叶癌病例进行回顾性队列研究,并提供临床和病理详细信息:总计2463名受试者共发生了2526例乳腺浸润性小叶癌。11/2463(0.45%)名受试者符合浸润性乳腺小叶癌局部复发的标准,发病率为1/224:结论:这对乳腺小叶癌患者的管理和随访具有临床意义。由于复发率较低,目前我们机构的标准做法是不提供磁共振成像(MRI)作为 ILC 患者随访的一部分。其他中心应确定当地的复发率,以帮助制定适当的管理方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.30
自引率
6.20%
发文量
133
审稿时长
6-12 weeks
期刊介绍: Journal of Medical Imaging and Radiation Oncology (formerly Australasian Radiology) is the official journal of The Royal Australian and New Zealand College of Radiologists, publishing articles of scientific excellence in radiology and radiation oncology. Manuscripts are judged on the basis of their contribution of original data and ideas or interpretation. All articles are peer reviewed.
期刊最新文献
Abstract. Abstract. Characterising high-risk plaque on cardiac CT. Evaluation of plan quality, safety, and toxicity of brachytherapy for locally advanced cervical cancer in an Australian setting following changes in prescription and applicator design. Lung cancer screening in Australia: The time approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1